Number of skin biopsies needed per malignancy: Comparing the use of skin biopsies among dermatologists and nondermatologist clinicians - 11/12/19
Abstract |
Background |
There are too few board-certified dermatologists to treat all patients with skin disease. Primary care physicians often serve at the frontline of skin cancer screening.
Objective |
To compare biopsy use among dermatologist physicians, dermatology advanced practice professionals (APPs), primary care physicians (PCPs), and other nondermatology clinicians.
Methods |
Pathology reports, requisition forms, and clinical notes of skin biopsies submitted to our institution during the study period were reviewed. Skin biopsies for inflammatory conditions, cosmetic or functional purposes, and re-excisions were excluded. The number needed to biopsy (NNB) was calculated as the number of biopsied lesions divided by histologically proven skin cancers.
Results |
The NNB by clinician type was 2.82 for dermatology physicians, 4.69 for APPs, 4.55 for nondermatology PCPs, and 6.55 for other nondermatology clinicians (P < .001). The NNB was significant between clinician groups for nonmelanoma skin cancer (dermatology physicians, 2.00; APPs, 2.71; PCPs, 2.36; and other nondermatology clinicians, 3.47; P < .001) but not for melanoma (dermatology clinicians, 14.33; APPs, 20.78; PCPs, 27.80; and other nondermatology clinicians, 53.56; P = .061).
Limitations |
The NNB represents a measure of use but gives no insight into the number of malignant lesions that go unbiopsied and, therefore, undiagnosed. The prevalence of skin cancer varies among dermatology and nondermatology practices. The results are not generalizable to all practice settings.
Conclusions |
Dermatology physicians had the lowest NNB of all clinician groups. PCPs performed similarly to dermatology APPs.
Le texte complet de cet article est disponible en PDF.Key words : biopsy use, number needed to biopsy, primary care physicians, skin cancer
Abbreviations used : APP, CI, NMSC, NNB, PCP
Plan
| Drs Bennett and Xu contributed equally to this article. |
|
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
Vol 82 - N° 1
P. 110-116 - janvier 2020 Retour au numéro
Article précédent
- Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis
- Ming-Ying Wu, Chia-Ling Yu, Shih-Jyun Yang, Ching-Chi Chi
- Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council
- Bruce Strober, Caitriona Ryan, Peter van de Kerkhof, Joelle van der Walt, Alexa B. Kimball, Jonathan Barker, Andrew Blauvelt, International Psoriasis Council Board Members and Councilors, Marc Bourcier, Andre Carvalho, Arnon Cohen, Peter Foley, Colby Evans, Paolo Gisondi, Chris Griffiths, Mahira Hamdy El-Sayed, Cristina Eschevarria, Andrew Finlay, Robert Kalb, Craig Leonardi, Chuck Lynde, Ruth Murphy, Masamoto Murakami, Yukari Okubo, Errol Prens, Lluís Puig, Marieke Seyger, Lone Skov, Tadashi Terui, Fernando Valenzuela, Nicole Ward, Jashin Wu, Min Zheng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?